What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation. 2018

Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
Innovative Drug Research and Bioinformatics Group, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou 310058 , China.

Dual inhibition of serotonin and norepinephrine transporters (hSERT and hNET) gives greatly improved efficacy and tolerability for treating major depressive disorder (MDD) compared with selective reuptake inhibitors. Pioneer studies provided valuable information on structure, function, and pharmacology of drugs targeting both hSERT and hNET (serotonin-norepinephrine reuptake inhibitors, SNRIs), and the differential binding mechanism between SNRIs and selective inhibitors of 5-HT (SSRIs) or NE (sNRIs) to their corresponding targets was expected to be able to facilitate the discovery of a privileged drug-like scaffold with improved efficacy. However, the dual-target mechanism of SNRIs was still elusive, and the binding mode distinguishing SNRIs from SSRIs and sNRIs was also unclear. Herein, an integrated computational strategy was adopted to discover the binding mode shared by all FDA approved SNRIs. The comparative analysis of binding free energy at the per-residue level discovered that residues Phe335, Leu337, Gly338, and Val343 located at the transmembrane domain 6 (TM6) of hSERT (the corresponding residues Phe317, Leu319, Gly320, and Val325 in hNET) were the determinants accounting for SNRIs' dual-acting inhibition, while residues lining TM3 and 8 (Ile172, Ser438, Thr439, and Leu443 in hSERT; Val148, Ser419, Ser420, and Met424 in hNET) contributed less to the binding of SNRIs than that of SSRIs and sNRIs. Based on these results, the distances between an SNRI's centroid and the centroids of its two aromatic rings (measuring the depth of rings stretching into hydrophobic pockets) were discovered as the key to the SNRIs' dual-targeting mechanism. This finding revealed SNRIs' binding mechanism at an atomistic level, which could be further utilized as structural blueprints for the rational design of privileged drug-like scaffolds treating MDD.

UI MeSH Term Description Entries
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin
D050484 Norepinephrine Plasma Membrane Transport Proteins Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of noradrenergic neurons. They remove NOREPINEPHRINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. The norepinephrine transporter regulates signal amplitude and duration at noradrenergic synapses and is the target of ADRENERGIC UPTAKE INHIBITORS. Neurotransmitter Transporters, Noradrenaline-Specific,Norepinephrine Plasma Membrane Transporter Proteins,Norepinephrine Plasma Membrane Transporters,NET Protein, Neuronal,Noradrenaline Plasma Membrane Transport Proteins,Noradrenaline Transporter,Norepinephrine Transporter,Norepinephrine Transporter Protein,SLC6A2 Protein,Sodium-Dependent Noradrenaline Transporter,Solute Carrier Family 6 Member 2,Neuronal NET Protein,Neurotransmitter Transporters, Noradrenaline Specific,Noradrenaline Transporter, Sodium-Dependent,Noradrenaline-Specific Neurotransmitter Transporters,Sodium Dependent Noradrenaline Transporter,Transporter Protein, Norepinephrine,Transporter, Noradrenaline,Transporter, Norepinephrine,Transporters, Noradrenaline-Specific Neurotransmitter
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics

Related Publications

Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
November 2004, Bioorganic & medicinal chemistry letters,
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
May 1998, European journal of pharmacology,
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
January 2019, Molecules (Basel, Switzerland),
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
February 2005, Bioorganic & medicinal chemistry letters,
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
September 2003, The Journal of biological chemistry,
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
August 2021, Paediatrics & child health,
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
January 2021, Pharmacy (Basel, Switzerland),
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
January 2021, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
April 2015, The Cochrane database of systematic reviews,
Weiwei Xue, and Fengyuan Yang, and Panpan Wang, and Guoxun Zheng, and Yuzong Chen, and Xiaojun Yao, and Feng Zhu
October 2015, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!